ScyFIX's Convertible Note - II Round

ScyFIX raised a round of funding on April 11, 2008.

ScyFIX uses targeted micro-current energy to address the Dry form of Macular Degeneration (AMD) and Retinitis Pigmentosa (RP). ScyFIX has completed two human Pilot clinical trials for RP and AMD that …

Articles about ScyFIX's Convertible Note - II Round: